【レポートの概要（一部）】
1. Report Overview
1.1 Global Ophthalmic Drugs: Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Ophthalmic Treatments – An Industry Overview
2.2 The Human Eyes – Structurally Delicate And Functionally Intricate Organs
2.3 The Global Burden Of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: A Major Cause Of Vision Loss
2.5.1 A Classification Of Glaucoma
2.5.1.1 Primary Open-Angle Glaucoma
2.5.1.2 Acute Angle-Closure Glaucoma
2.5.1.3 Congenital Glaucoma
2.5.1.4 Secondary Glaucoma
2.5.1.5 Normal-Tension Glaucoma
2.5.1.6 Ocular Hypertension
2.5.2 Risk Factors For Glaucoma
2.5.3 Diagnosis Of Glaucoma
2.5.4 Drug Treatment Of Glaucoma
2.5.5 Laser Treatment And Surgery For Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors For AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis Of Diabetic Retinopathy
2.7.2 Treatment Of Diabetic Retinopathy
2.8 Ocular Allergy And Allergic Conjunctivitis
2.8.1 Diagnosis Of Ocular Allergy
2.8.2 Treatment Of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Treatment Of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment Of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome
2.12 Phases of Clinical Trials
2.13 Ophthalmic Drugs: Market Definition In This Report
3. The Global Ophthalmic Drugs Market, 2016-2026
3.1 The Global Ophthalmic Drugs Market: Market Overview
3.2 Categorisation of the Global Ophthalmic Drugs Market
3.3 The Global Ophthalmic Drugs Market In 2015
3.4 The Global Ophthalmic Drugs Market: Market Forecast 2016-2026
3.5 Ophthalmic Drugs: Changing Market Shares by Sector 2016-2026
4. The Retinal Disorder Drugs Market: Market Analysis and Forecast 2016-2026
4.1 Leading Products in the Retinal Disorder Drugs Market, 2015
4.2 Retinal Disorders: Market Trends And Developments, 2016
4.2.1 The Rise And Rise Of Eylea
4.2.2 The Debate Around Off-Label Avastin Use And The Role Of Novartis And Roche
4.2.3 How Likely Is Avastin’s Expansion Into Age-Related Macular Degeneration?
4.2.4 Jetrea: Underwhelming Sales Cause ThromboGenics to Switch Focus to Their Pipeline
4.2.5 Drug/Device Combination Products Entering The Market
4.2.6 Does Regenerative Medicine Have A Successful Future In Ophthalmics?
4.3 Retinal Disorder Drugs: Market Forecast 2016-2026
4.3.1 Retinal Disorder Drugs: Changing Market Shares By Leading Drugs 2016-2026
4.4 Leading Drugs For The Treatment Of Retinal Disorders
4.5 Eylea (aflibercept) – Regeneron/ Bayer/ Santen
4.5.1 Recent Approvals For Eylea
4.5.2 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.5.3 Eylea: Sales Forecast 2016-2026
4.5.4 Possible Combination Therapies Involving Eylea
4.6 Lucentis (ranibizumab) – Roche/ Novartis
4.6.1 Lucentis: Sales Forecast 2016-2026
4.6.2 Less Frequent Dosing Approved In US For Lucentis
4.6.3 New Indications For Lucentis
4.6.4 Possible Combination Therapy Involving Lucentis
4.7 Avastin (bevacizumab) – Roche
4.7.1 Avastin: Sales Forecast 2016-2026
4.7.2 Compounding Pharmacies And Safety Risks
4.8 Visudyne (verteporfin) – Valeant/ Novartis
4.8.1 Visudyne: Sales Forecast 2016-2026
4.9 Jetrea (ocriplasmin) – ThromboGenics/ Novartis
4.9.1 Jetrea: Recent Sales Performance
4.9.2 Clinical Study Plans For Jetrea
4.9.3 Jetrea: Sales Forecast 2016-2026
4.9.4 Possible Acquisition Move On ThromboGenics
4.9.5 R&D Agreements With Eleven Biotherapeutics and Bicycle Therapeutics
4.10 Other Retinal Disorder Drugs
4.10.1 Iluvien (fluocinolone implant) – Alimera Sciences
4.10.2 Ozurdex (dexamethasone implant) – Allergan
4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2016-2026
5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis And Forecast 2016-2026
5.1 Leading Products In The Allergic, Inflammatory And Infective Drugs Market, 2015
5.2 Allergic, Inflammatory And Infective Drugs: Market Trends And Developments, 2016
5.2.1 The Growth Prospects For Allergic, Inflammatory And Infective Drugs
5.2.2 Topical NSAIDs Launched: Prolensa and Ilevro
5.3 Allergic, Inflammatory And Infective Drugs: Market Forecast 2016-2026
5.3.1 Allergic, Inflammatory And Infective Drugs: Changing Market Shares By Leading Drugs 2016-2026
5.4 Leading Drugs For The Treatment Of Allergic, Inflammatory And Infective Ophthalmic Conditions
5.5 Patanol And Pataday (olopatadine) – Alcon (Novartis)
5.5.1 Pataday: Sales Forecast 2016-2026
5.5.2 Impending Generic Competition For Patanol And Pataday
5.5.3 Approval Of Pazeo Solution
5.5.4 Patanol: Sales Forecast 2016-2026
5.6 Vigamox (moxifloxacin) – Alcon (Novartis)
5.6.1 Intensifying Competition And Generics Drug Challenge To Vigamox
5.6.2 Moxeza: A Next-Generation Form of Vigamox
5.6.3 Vigamox: Sales Forecast 2016-2026
5.7 TobraDex (tobramycin/dexamethasone) – Alcon (Novartis)
5.7.1 The Development And Commercialisation Of TobraDex ST
5.7.2 TobraDex: Sales Forecast 2016-2026
5.8 Cravit (levofloxacin) – Santen
5.8.1 Cravit: Sales Forecast 2016-2026
5.9 Acular (ketorolac) – Allergan (Actavis)
5.9.1 5.9.1 Acular: Sales Forecast 2016-2026
5.10 AzaSite (azithromycin) – Akorn
5.10.1 AzaSite: Sales Forecast 2016-2026
5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast 2016-2026
6. Glaucoma Drugs Market: Market Analysis And Forecast 2016-2026
6.1 Glaucoma Drugs: Market Overview
6.1.1 Leading Products In The Glaucoma Drugs Market, 2015
6.2 Glaucoma Drugs: Market Trends And Developments, 2016
6.2.1 Patent Expiration: A Major Restraint For Glaucoma Drugs
6.2.2 Preservative-Free Formulation Trends
6.2.3 Innovation In Treatments For Glaucoma
6.3 Simbrinza: First Beta-Blocker-Free Combination
6.4 Glaucoma Drugs: Market Forecast 2016-2026
6.4.1 Glaucoma Drugs: Changing Market Shares By Leading Drugs 2016-2026
6.5 Leading Drugs For The Treatment Of Glaucoma
6.6 Lumigan And Ganfort (bimatoprost) – Allergan (Actavis)
6.6.1 Lumigan And Ganfort: Sales Forecast 2016-2026
6.7 Xalatan And Xalacom (latanoprost) – Pfizer
6.7.1 Xalatan/Xalacom: Sales Forecast 2016-2026
6.8 Travatan/Travatan Z And DuoTrav (travoprost) – Novartis
6.8.1 Travatan/Travatan Z And DuoTrav: Sales Forecast 2016-2026
6.9 Alphagan/Alphagan P And Combigan (brimonidine) – Allergan
6.9.1 Alphagan/Alphagan P And Combigan: Sales Forecast 2016-2026
6.10 Trusopt And Cosopt/Cosopt PF (dorzolamide) – Merck/ Santen
6.10.1 Divestment Agreement With Santen And Akorn
6.10.2 Trusopt: Sales Forecast 2016-2026
6.10.3 Cosopt And Cosopt PF: Sales Forecast 2016-2026
6.11 Azopt (brinzolamide) – Novartis
6.11.1 Azopt: Sales Forecast 2016-2026
6.12 Tapros (tafluprost) – Santen
6.12.1 Tapros: Sales Forecast 2016-2026
6.13 Zioptan (tafluprost) – Akorn
6.13.1 Zioptan: Sales Forecast 2016-2026
6.14 Other Glaucoma Drugs: Sales Forecast 2016-2026
7. Dry Eye Drugs Market: Market Analysis And Forecast 2016-2026
7.1 Dry Eye Drugs: Market Overview
7.1.1 Leading Products In The Dry Eye Drugs Market, 2015
7.2 Dry Eye Drugs: Market Trends And Developments, 2016
7.2.1 Restasis: Patent Elongations And Generic Challenges Creating Uncertainty
7.2.2 Intensifying Research Focused On Dry Eye
7.2.3 Improving Diagnostic Tools
7.3 Dry Eye Drugs: Market Forecast 2016-2026
7.3.1 Dry Eye Drugs: Changing Market Shares By Leading Drugs 2016-2026
7.4 Leading Drugs For The Treatment Of Dry Eye
7.5 Restasis (ciclosporin) – Allergan (Actavis)
7.5.1 Restasis – Generic launch in 2016?
7.5.2 Restasis: Sales Forecast 2016-2026
7.6 Refresh Brand Products – Allergan (Actavis)
7.6.1 Refresh Brand Products: Sales Forecast 2016-2026
7.7 Hyalein (hyaluronic acid) – Santen
7.7.1 Hyalein: Sales Forecast 2016-2026
7.8 Diquas (diaquafosol) – Santen
7.8.1 Diquas: Sales Forecast 2016-2026
7.9 Other Dry Eye Drugs: Sales Forecast 2016-2026
7.10 Other Ophthalmic Drugs
7.10.1 Hetlioz (tasimelteon) – Vanda Pharmaceuticals
7.10.2 Hetlioz: Sales Forecast 2016-2026
8. Leading National Markets For Ophthalmic Drugs, 2016-2026
8.1 The Ophthalmic Drugs Market By Region
8.1.1 The Global Distribution Of Ophthalmic Drugs In 2015
8.2 Leading National Markets: Forecast 2016-2026
8.2.1 Changing Market Shares By Region, 2016-2026
8.3 Regional Ophthalmic Drugs Markets: Analysis And Forecasts, 2016-2026
8.4 United States: The Largest Ophthalmic Drugs Market
8.4.1 How Will The Rise Of A Biosimilars Market Impact On US Ophthalmic Drugs?
8.4.2 US Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5 EU5
8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2016-2026
8.5.2 Germany
8.5.2.1 German Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5.3 France
8.5.3.1 French Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5.4 UK
8.5.4.1 UK Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5.4.2 Brexit – Increased Uncertainty May Affect the UK Ophthalmic Drug Market
8.5.5 Italy
8.5.5.1 Italian Ophthalmic Drugs Market: Market Forecast 2016-2026
8.5.6 Spain
8.5.6.1 Spanish Ophthalmic Drugs Market: Market Forecast 2016-2026
8.6 Japan
8.6.1 The Cost Of Treatment In Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Ophthalmic Drugs Market Forecast 2016-2026
8.7 8.7 China
8.7.1 Expansion Of Healthcare Coverage and Reimbursement in China
8.7.2 Price Controls And The Anhui Model
8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2016-2026
8.8 Brazil
8.8.1 How Will Brazil’s Growing Healthcare Influence Ophthalmic Drugs
8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2016-2026
8.9 Russia
8.9.1 How Will Russia’s Economic Status Affect Its Pharma Industry?
8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2016-2026
8.10 India
8.10.1 The Impact Of The Drug Prices Control Order On Indian Pharma
8.10.2 India’s Expansion Of Healthcare Provision
8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2016-2026
8.11 Rest of the World
8.11.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2016-2026
9. Leading Companies in the Ophthalmic Drugs Market, 2016-2026
9.1 Ophthalmic Drugs – A Changing Market Landscape
9.2 Leading Companies In The Ophthalmic Drugs Market, 2015
9.2.1 Ophthalmic Drugs Market: Leading Companies Forecast 2016-2026
9.2.2 Ophthalmic Drugs: Changing Market Shares By Leading Companies 2016-2026
9.3 Novartis (Alcon)
9.3.1 Novartis: Ophthalmic Drugs Portfolio, 2015
9.3.2 Novartis: Sales Forecast 2016-2026
9.3.3 Novartis: Ophthalmic Drugs Development Pipeline, 2016
9.3.4 Novartis: Recent Developments
9.3.4.1 Novartis Restructures Following Strategic Review
9.3.4.2 Novartis Licenses Ophthotech’s Fovista
9.4 Regeneron
9.4.1 Regeneron: Ophthalmic Drugs Portfolio, 2015
9.4.2 Regeneron: Recent Developments
9.4.2.1 Expanding Indications For Eylea
9.4.2.2 Eylea/Zaltrap And The Davis-Smyth Patent Agreements
9.4.3 Regeneron: Sales Forecast 2016-2026
9.4.4 Regeneron: Ophthalmic Drugs Development Pipeline, 2015
9.5 Allergan (Actavis)
9.5.1 Allergan: Ophthalmic Drugs Portfolio
9.5.2 Allergan: Recent Developments
9.5.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
9.5.2.2 How Real Is The Threat Of Generic Restasis?
9.5.2.3 Valeant’s Attempted Takeover Squashed By Actavis Bid
9.5.3 Allergan: Sales Forecast 2016-2026
9.5.4 Allergan: Ophthalmic Drugs Development Pipeline, 2016
9.6 Roche
9.6.1 Roche: Ophthalmic Drugs Portfolio, 2016
9.6.1.1 Lucentis: US Sales Forecast 2016-2026
9.6.2 Roche: Sales Forecast 2016-2026
9.6.3 Roche: Ophthalmic Drugs Development Pipeline, 2016
9.7 Valeant
9.7.1 Valeant: Ophthalmic Drugs Portfolio, 2015
9.7.2 Valeant: Recent Developments
9.7.2.1 Valeant’s Acquisition of Bausch and Lomb Still Driving Its Ophthalmic Portfolio
9.7.3 Valeant: Sales Forecast 2016-2026
9.7.4 Valeant: Ophthalmic Drugs Development Pipeline, 2016
9.7.5 Valeant: Difficult End to 2015 Leads to Uncertainty About Company Future
9.8 Santen
9.8.1 Santen: Ophthalmic Drugs Portfolio, 2015
9.8.2 Santen: Recent Developments
9.8.2.1 Santen Acquires Novagali Pharma
9.8.2.2 Santen Acquires Merck’s Ophthalmic Drugs Portfolio
9.8.3 Santen: Sales Forecast 2016-2026
9.8.4 Santen: Ophthalmic Drugs Development Pipeline, 2016
9.9 Bayer
9.9.1 Bayer: Ophthalmic Drugs Portfolio
9.9.2 Bayer: Sales Forecast 2016-2026
9.10 Pfizer
9.10.1 Pfizer: Ophthalmic Drugs Portfolio, 2016
9.10.1.1 Xalatan/Xalacom – Pfizer’s Leading Ophthalmic Products
9.10.1.2 Macugen – Valeant/Pfizer
9.10.2 Pfizer: Recent Developments
9.10.2.1 Pfizer Attempts to Acquire AstraZeneca
9.10.2.2 Pfizer Attempts Merger with Allergan
9.10.3 Pfizer: Sales Forecast 2016-2026
9.10.4 Pfizer: Ophthalmic Drugs Development Pipeline, 2016
9.11 Senju
9.11.1 Senju: Ophthalmic Drugs Portfolio
9.11.2 Senju: Sales Forecast 2016-2026
9.11.3 Senju: Ophthalmic Drugs Development Pipeline, 2016
9.11.3.1 Y 39983 (SNJ 1656)
9.11.3.2 Difluprednate (SJE-2079)
10. Ophthalmic Drugs: Research And Development Pipeline, 2016-2026
10.1 The Ophthalmic Drugs Pipeline: Intensive Development Efforts In Retinal Disorders
10.2 Drugs For Retinal Disorders: Development Pipeline, 2016
10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
10.3 Retinal Disorders: Filed or Recently Launched
10.3.1 Compaq Sipp (conbercept) – Chengdu Kanghong Pharmaceutical
10.3.2 Lipidil (fenofibrate) – Abbott
10.3.3 Iluvien (fluocinolone) – Alimera Sciences
10.4 Drugs In Phase 3 Development For Retinal Disorders
10.4.1 AGN150998 And MP0260 (Anti-VEGF DARPins) – Allergan
10.4.2 Fovista and Zimura – Ophthotech Corporation
10.4.3 Lampalizumab (anti-Factor D Fab) – Roche
10.4.4 MC-1101 (hydralazine) – MacuCLEAR
10.4.5 Squalamine (anti-angiogenic drug) – OHR Pharmaceutical
10.4.6 Tandospirone (serotonin 1A agonist) – Alcon (Novartis)
10.4.7 UF-021 (unoprostone) – R-Tech Ueno
10.5 Drugs In Phase 2 Development For Retinal Disorders
10.5.1 AKB-9778 (Tie2 activator) – Aerpio Therapeutics
10.5.2 Luminate (ALG-1001; Integrin peptide therapy) – Allegro/Senju
10.5.3 AGN208397 (beclomethasone) – Allergan
10.5.4 CPC 551 – Colby Pharmaceutical
10.5.5 ESBA1008 (anti-VEGF mAb) – Alcon (Novartis)
10.5.6 iCo-007 (antisense inhibitor of C-raf kinase mRNA) – iCo Therapeutics
10.5.7 LFG316 (anti-C5 mAb) – Novartis
10.5.8 Intravitreal brimonidine implant – Allergan
10.5.9 Optina (danazol) – Ampio Pharmaceuticals
10.5.10 PF-655 (synthetic siRNA) – Quark/Pfizer
10.5.11 Premiplex (SHP-607) – Shire
10.5.12 Renexus (ciliary neurotrophic factor) – Neurotech
10.5.13 Zybrestat (fosbretabulin) – Oxigene/Symphony VIDA
10.6 Drugs In Phase 1 and Pre-clinical Development for Retinal Disorders
10.6.1 BDM-E – BioDiem
10.6.2 NADPH Oxidase Inhibitors – Alimera Sciences
10.6.3 PAN-90806 (topical VEGF inhibitor) – PanOptica
10.6.4 Plasma Kallikrein Inhibitors (KVD001) – KalVista
10.6.5 QLT091001 (synthetic retinoid) – QLT
10.7 Drugs For Allergic, Inflammatory And Infective Ophthalmic Conditions: Development Pipeline, 2016
10.8 Drugs In Phase 3 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
10.8.1 EGP-437 (dexamethasone) – EyeGate Pharmaceuticals
10.8.2 IBI-10090 and IBI-20089 – Icon Bioscience
10.8.3 KPI-121 (loteprednol etabonate) – Kala
10.9 Drugs In Phase 2 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
10.9.1 CF101 (adenosine A3 receptor agonist) – Can-Fite BioPharma and OphthaliX
10.9.2 FST-100 (povidone-iodine/dexamethasone) – Shire
10.9.3 NVC-422 (auriclosene) – NovaBay
10.9.4 Sarilumab – Regeneron
10.10 Drugs In Phase 1 And Pre-clinical Development For Allergic, Inflammatory and Infective Ophthalmic Conditions
10.10.1 Finafloxacin – MerLion Pharmaceuticals/Novartis
10.11 Drugs For Glaucoma: Development Pipeline, 2016
10.12 Drugs In Phase 2&3 Development For Glaucoma
10.12.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) – Valeant
10.12.2 AMA0076 (ROCK inhibitor) – Amakem
10.12.3 Rhopressa (AR-13324; ROCK and NET inhibitor) And Roclatan (PG324; ROCK inhibitor) – Aerie Pharmaceuticals
10.13 Drugs In Phase 1 And Pre-clinical Development For Glaucoma
10.14 Drugs For Dry Eye: Development Pipeline, 2016
10.15 Drugs In Phase 3 Development For Dry Eye
10.15.1 EBI-005 (IL-1R antagonist) – Eleven Biotherapeutics
10.15.2 Lifitegrast (integrin antagonist) – Shire
10.15.3 Tavilermide (formerly MIM-D3 tyrosine kinase receptor antagonist) – Allergan
10.15.4 SI-614 (modified hyaluronate) – Seikagaku
10.16 Drugs In Phase 2 Development For Dry Eye
10.16.1 ESBA105 (TNF-alpha antibody) – Alcon (Novartis)
10.16.2 Kineret (anakinra: IL-1 receptor antagonist) – Amgen/Sobi
10.17 Other Drugs In The Development Pipeline For Ophthalmic Conditions
10.17.1 Brimonidine For Eye Whitening – Valeant
10.17.2 GS-101 (aganirsen) – Gene Signal
10.17.3 Omidria (phenylephrine/ketorolac) – Omeros
11. Qualitative Analysis Of The Ophthalmic Drugs Market, 2016-2026
11.1 Market Factors Influencing Ophthalmic Drugs
11.2 SWOT Analysis Of The Global Ophthalmic Drugs Market, 2016-2026
11.3 Strengths
11.3.1 A Healthy R&D Pipeline
11.3.2 Advances In Drug Delivery Technologies
11.3.3 Support For Reimbursement And Payment Approvals
11.3.4 Gene Therapy And RNAi Technology
11.3.5 New Ophthalmic Therapeutic Applications For Drugs
11.3.6 Development Of Neuroprotective Anti-Glaucoma Medications
11.3.7 Biomarkers As Tools For Better Diagnosis And Treatment
11.4 Weaknesses
11.4.1 Low Levels of Patient Adherence To Treatment
11.4.2 High Treatment Burden On Patients And Healthcare Providers
11.4.3 Under-Diagnosis And Under-Treatment
11.5 Opportunities
11.5.1 Sustained-Release Ocular Implants
11.5.2 The Impact Of A Rapidly Ageing Global Population
11.5.3 Increasing Prevalence of Diabetes and Ocular Disease
11.5.4 Glaucoma And Retinal Disorders Set for Most-Marked Increases in Prevalence
11.5.5 Unmet Clinical Need In Many Disease Areas
11.5.6 Economic Growth In Emerging Market Provide Opportunity For Expansion
11.6 Threats
11.6.1 Intensifying Price Regulation In The Market
11.6.2 Generic Competition – Likely to Cause Erosion of Sales for Market Leading Brands
11.6.3 Rising Cost Of R&D
11.6.4 Biosimilars – A Bigger Threat than Generics?
11.7 Porter’s Five Force Analysis Of The Global Ophthalmic Drugs Market, 2016-2026
11.7.1 Threat of New Entrants
11.7.2 Rivalry Among Competitors
11.7.3 Power of Suppliers
11.7.4 Threat of Substitutes
11.7.5 Power of Buyers
12. Conclusions
12.1 Overview Of Current Market Conditions And Market Forecast, 2015-2026
12.2 Leading Sectors In Ophthalmic Drugs In 2015
12.3 Leading Regions In The Ophthalmic Drugs Market In 2015
12.4 Leading Companies In The Ophthalmic Drugs Market, 2015
12.5 What Does The Future Hold For Ophthalmic Drugs?
13. Glossary
【レポート販売概要】
■ タイトル：眼薬の世界市場予測2016-2026■ 英文：Ophthalmic Drugs Market Forecast 2016-2026
■ 発行日：2016年7月
■ 調査会社：visiongain
■ 商品コード：VGAIN81924
■ 調査対象地域：グローバル
- ビルディングインフォメーションモデリングソフトウェアの世界市場2016-2020About BIM Software Factors, such as government mandates and support to use BIM solutions in construction projects, are driving the growth of the global BIM market. Governments in countries such as the US, the UK, and Singapore are promoting the use of BIM in construction as it helps to minimize errors and time taken for the execution of the construction projects. BIM software enables the creation …
- キッチンシンクの世界市場2019-2023About this market The APAC is expected to be the major contributor to the global residential building construction market led by rising urbanization and growing disposable income. As houses are considered a long-term asset. the people started investing on it to secure the future. In addition, house owners can rent the house as rent is a non-detectible expense. The growth in residential building co …
- 世界のユーティリティー産業におけるGIS市場動向（2012-2016）TechNavio's analysts forecast the Global GIS market in the Utility industry to grow at a CAGR of 10.37 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing need for knowledge infrastructure. The Global GIS market in the Utility industry has also been witnessing increasing focus on application-specific GIS solutions. However, the lack of awa …
- 芳香物質の世界市場：天然芳香物質、合成芳香物質About Aroma Chemicals Aroma chemicals are ingredients used to impart fragrance to various end-use products. This market can be segmented into natural and synthetic aroma chemicals. The Global Aroma Chemicals market is expected to witness a healthy growth during the forecast period. It is primarily driven by the demand from companies that manufacture food, soaps and detergents, cosmetics, toiletrie …
- 世界の鉛市場：市場規模、動向、メーカー動向Scope The report presents a thorough study of lead, covering both global and regional markets It aims to give a proper picture of the market, as well as its trends, perspectives and opportunities Comprehensive data showing lead production, consumption, trade statistics and prices are provided (both nationwide and worldwide) Each country’s market overview covers the following: lead production in th …
- セルラーM2M通信およびサービスの世界市場2016-2020About the Cellular M2M Connections and Services Market M2M technology enables the communication of data and information between electronic devices. In cellular M2M connections, code-division multiple access (CDMA), 2G, 3G, and 4G-LTE networks are used to establish connections between electronic devices. Cellular M2M has a broad range of applications in industries such as automotive, healthcare, re …
- LTE以後のキャリアWiFi及びスモールセル：市場機会及び予測2013-2018（Carrier WiFi and Small Cells in LTE & Beyond: Market Opportunities and Forecasts 2013 – 2018）WiFi and small cells deployments minimize network planning, redesign and real estate costs. Deploying them also allows carriers to avoid or minimize new frequency allocation costs. Small Cells can in many cases utilize the same frequency spectrum that carrier has allocated for its macro cell deployment, while WiFi access points utilize unlicensed spectrum. Not only do WiFi and small cells deployme …
- スチレン・ブタジエン・スチレン（SBS）ブロック共重合体の世界市場2019-2023About this market Digital transformation across industries like healthcare, transportation and logistics, retail, hospitality, and manufacturing are driving the growth of global labor management software market. The market has witnessed a technological advancement such as like IoT, cloud computing, big data, and analytics, and augmented reality in the labor management software to improve the effic …
- 動物創傷ケアの世界市場予測：縫合糸、シーラント、接着剤、フィルム、フォーム、ハイドロゲル、ハイドロコロイド包帯、包帯、絆創膏、吸収剤、テープ、NPWTデバイスThe animal wound care market is expected to witness significant growth in the coming years. The global market is projected to reach USD 1,134.0 Million by 2021 from USD 818.8 Million in 2016, at a CAGR of 6.7% from 2016 to 2021. Factors such as growing population of companion as well as livestock animals; rising demand for pet insurance along with increasing animal healthcare expenditure; and incr …
- 電子産業におけるコンフォーマルコーティングの世界市場2017-2021About Conformal Coating in Electronics Conformal coatings are materials that are applied in thin layers (0.002 to 0.005 inch) on electronic substrates to provide environmental and mechanical protection. These coatings protect and cover printed circuit boards (PCBs) and other electrical components from harsh environmental conditions such as moisture, dirt, abrasion, fungus, chemicals, mechanical st …
- 複合材用不飽和ポリエステル樹脂（UPR）の世界市場2016-2026Are you involved in the unsaturated polyester resin (UPR) market for composites or intend to be? If so, then you must read this report It’s vital that you keep your knowledge up to date with market developments. Visiongain’s new 169 page report assesses that the global unsaturated polyester resin (UPR) for composites market will reach $7.97 billion in 2016. Market scope: This brand new report from …
- 世界の軍事航空MRO（保守、修理、点検）市場（2014-2024）Summary The Global Military Aviation MRO Market 2014-2024 Report published by Strategic Defence Intelligence, provides readers with a detailed analysis of both historic and forecast global industry values, factors influencing demand, the challenges faced by industry participants, analysis of industry leading companies, and key news. Key Findings - The global military aviation MRO market is expecte …
- サーバの世界市場予測2014-2018This research report presents shipment volume and value forecasts and recent quarter review of the Taiwanese server system and server motherboard industries. The report includes server full system, barebone, and motherboard shipment volume, shipment value, ASP, volume and share by maker and by price point, and manufacturer volume ranking. The report analyzes shipment by CPU architecture and CPU co …
- 照明器具用安定器の世界市場2016-2020About Lighting System In lighting system, the major role of a ballast is to regulate the current to the bulb or tube and provide necessary voltage to start the bulb and produce a steady light output. If the lighting source is connected directly to high-voltage power source, it will draw more current to the bulb or tube and will quickly burn out before its expected lifecycle. Therefore, ballast pro …
- 不眠症治療薬の世界市場2015-2019About insomnia Insomnia or sleeplessness is characterized by the difficulty in falling asleep or remaining asleep, resulting in poor quality of sleep or little sleep. Sleeplessness can be acute or chronic. Work-related stress is the more common factor for acute or primary insomnia, while medical conditions, such as arthritis, or medicines, such as amphetamines, and substances, such as cocaine, are …
